Genmab (GMAB) Earnings Analysis

Genmab (GMAB) next reports earnings on 2026-08-06, consensus EPS 0.35 USD. Last quarter (2026-05-07) it missed with EPS 0.087 USD vs 0.15 USD est (-42%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E 21.61.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does GMAB next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate0.35 USD
Revenue estimate1.11B

GMAB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-070.087 USD0.15 USD-42%Miss
2026-02-170.05 USD0.46 USD-89.1%Miss
2025-11-060.65 USD0.48 USD+35.4%Beat
2025-08-070.54 USD0.39 USD+38.5%Beat
2025-02-120.57 USD0.28 USD+103.6%Beat

Beat rate: 3/5 (60%) over reported quarters with consensus data.

GMAB valuation and analyst view

Trailing P/E21.61
Trailing EPS1.34 USD
Price / book3.11
Dividend yield0.00%
Market cap17.82B
Analyst consensusBuy (13 buy / 4 hold / 1 sell)
Avg price target40.33 USD

Related research pages

Frequently asked questions

When is Genmab (GMAB)'s next earnings date?

Genmab is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 0.35 USD and revenue estimate of 1.11B.

Did GMAB beat earnings last quarter?

In its 2026-05-07 report, GMAB posted EPS of 0.087 USD versus a 0.15 USD estimate — a miss of 42%.

What is GMAB's earnings track record?

Over the last 5 reported quarters with consensus data, GMAB beat estimates 3 times (60%).

What is GMAB's current P/E ratio and EPS?

GMAB trades at a trailing P/E of 21.61 on trailing EPS of 1.34 USD.

What do analysts rate GMAB?

Analyst consensus is "Buy" across 18 ratings (0 strong buy, 13 buy, 4 hold, 1 sell, 0 strong sell). Average 12-month price target: 40.33 USD.